Aurobindo Pharma, MSN Labs seek DGCI nod for Phase-III trials of Merck’s molnupiravir, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

Last week, Aurobindo Pharma and MSN Laboratories presented the interim clinical trial data in moderate patients before the the Subject subject expert committee (SEC) — the expert panel under the Drug Controller General of India (DCGI)., Last week, Aurobindo Pharma and MSN Laboratories presented the interim clinical trial data in moderate patients before the the Subject subject expert committee (SEC) — the expert panel under the Drug Controller General of India (DCGI)., , Read More